Episode notes
In this episode, Dr. Chris Austin, Senior Vice President of Research Technologies at GSK, joins Neil to share how artificial intelligence, genetics, and vast clinical datasets are radically reshaping the pharmaceutical landscape. A neurologist by training with experience across the NIH, biotech startups, and now GSK, Chris explains how drug development is finally moving beyond trial-and-error toward predictive, precision-based approaches.
He reveals how GSK is:
- Using AI and genomics to map disease “circuits” and prioritize drug targets with greater accuracy
- Designing novel molecules like oligonucleotides to reach previously “undruggable” targets
- Streamlining clinical trials through deep phenotyping and biomarker-based patient selection
- Leveraging generative AI to model disease biology, simulate clinical ou ...
Keywords
GSK